Abstract
Myositis-specific autoantibodies (MSAs) are hallmarks of idiopathic inflammatory myopathies (IIMs) and have become increasing valuable in disease diagnosis, phenotyping, and classification. In addition to their clinical utility, emerging data, including findings from several animal studies, suggest that MSAs and autoreactive T cells substantially contribute to the etiopathogenesis of IIMs. This review aims to provide an updated perspective on myositis autoantibodies by focusing on relevant clinical and translational studies.
Original language | English |
---|---|
Number of pages | 8 |
Journal | Clinical and Experimental Rheumatology |
Early online date | 31 Oct 2024 |
DOIs | |
Publication status | E-pub ahead of print - 31 Oct 2024 |